This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at fraseg@mmc.org or Sandra Kane-Gill, PharmD, MSc, at kanesl@upmc.edu.
Get full access to this article
View all access options for this article.
References
1.
HoffmanM., MonroeDMIII, RobertsH.R.Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis.1998; 9(Suppl 1): S61–S65.
2.
MohrA.M., HolcombJ.B., DuttonR.P., DuranteauJ.Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care.2005; 9(Suppl 5): S37–S42.
3.
DuttonR.P., McCunnM., HyderM., D'AngeloM., O'ConnorJ., HessJ.R., ScaleaT.M.Factor VIIa for correction of traumatic coagulopathy. J Trauma.2004; 57: 709–718.
4.
HarrisonT.D., LaskoskyJ., JazaeriO., PasqualeM.D., CipolleM.“Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma.2005; 59(1): 150–154.
5.
BoffardK.D., RiouB., WarrenB.. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma.2005; 59: 8–18.
6.
MayerS.A., BrunN.C., BroderickJ.. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke.2005; 36(1): 74–79.
7.
ShanderA., GoodnoughL.T., RatkoT.. Consensus recommendations for the of-label use of recombinant human factor VIIa (Novoseven) therapy. J Clin Pharm Ther.2005; 30(11): 644–658.
8.
MengZ.H., WolbergA.S., MonroeDMIII, HoffmanM.The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma.2003; 55: 886–891.
9.
SteinD.M., DuttonR.P., O'ConnorJ., AlexanderM., ScaleaT.M.Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma.2005; 59(3): 609–615.
10.
Novoseven [package insert].Denmark; Novo Nordisk: 2005.
11.
MayerS.A., BrunN.C., BegtrupK.. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med.2005; 352: 777–785.
12.
O'ConnellK.A., WoodJ.J., WiseR.P., LozierJ.N., BraunM.M.Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA.2006; 295(3): 293–298.
13.
BauerK.A.Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis.1996; 26(Suppl 1): 155–158.
